CoChat
Sign Up
Cited by 14Alzheimer's disease research and treatmentsHIV Research and TreatmentHIV-related health complications and treatments

Blood amyloid-β protein isoforms are affected by HIV-1 in a subtype-dependent pattern

Open access
The HIV Neurobehavioral Research Center (HNRC) Group, de Almeida, Sérgio M., Ribeiro, Clea E., Rotta, Indianara, Letendre, Scott, Potter, Michael, Tang, Bin, Batistela, Meiri +2 more·2020·Journal of NeuroVirology
DOI 10.1007/s13365-019-00783-6PMC PMC6944779
Open this paper in CoChat — free account

Abstract

This study aimed to compare serum amyloid processing biomarkers among HIV subtype B (n = 25), HIV subtype C (n = 26), healthy HIV-negative controls (n = 18), and patients with Alzheimer's disease (AD; n = 24). Immunoassays were used to measure main soluble Aβ isoforms Aβ38, Aβ40, Aβ42, and Aβ-total in serum and cerebrospinal fluid (CSF). People living with HIV (PLWH) and HIV(-) samples, including AD samples, were compared for gender and age, while HIV subtypes were compared for nadir CD4 and plasma viral load suppression. CSF/serum ratios of Aβ40, Aβ42, and Aβ-total were lower in HIV-1C group than in HIV-1B group (p = 0.020, 0.025, and 0.050, respectively). In serum, these biomarkers were comparable. Serum Aβ isoforms were significantly lower in PLWH than in AD. Serum Aβ42 levels in PLWH were decreased compared to those in control group, thus similar to Aβ42 alterations in CSF; these results were different from those observed in AD. Impaired cellular immunity, low CD4 cell count (nadir or current) influences serum Aβ metabolism in HIV-1B but not HIV-1C. However, in PLWH overall, but not in individual HIV subtype groups, greater CD4 recovery, calculated as the difference between current and nadir CD4, correlated with Aβ42/Aβ40 ratio in serum (r s 0.246; p = 0.0479). No significant correlation was found with global deficit score (GDS), an index of neurocognitive performance, age, or duration of infection. These findings are consistent with those of subtype-dependent amyloid processing in blood in chronic HIV disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13365-019-00783-6

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In this cohort and others, individuals who had HIV-associated dementia or HAND had the lowest levels of Aβ40 and Aβ42.

    “In this cohort and others, individuals who had HIV-associated dementia or HAND had the lowest levels of Aβ40 and Aβ42 [114–116].”

    From What would it take to prove that a chronic infection is a causal agent in Alzheimer’s disease? (2025) · cites this paper as [115]

    The Results (‘Serum Aβ in PLWH, HIV(−), and AD patients’; page unavailable) report lower serum Aβ40 and Aβ42 in people with HIV than in the Alzheimer’s disease group, and lower Aβ42 than in HIV-negative controls. They do not establish that individuals with HIV-associated dementia or HAND had the lowest levels; the Discussion reports no correlation between neurocognitive performance and serum Aβ biomarkers. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 55

  1. Aksenov MY, Aksenova MV, Mactutus CF, (2010) HIV-1 protein-mediated amyloidogenesis in rat hippocampal cell cultures. Neurosci Lett. 475: 174– 178. 20363291 PMC2874942
  2. Andras IE, Toborek M (2013) Amyloid Beta Accumulation in HIV-1-Infected Brain: the Role of the Blood Brain Barrier. IUBMB Life 65: 43– 49. 23225609 PMC3804005
  3. Brew BJ, Pemberton L, Blennow K, (2005) CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology 65: 1490– 1492. 16275845
  4. Brown LAM, Jin J, Ferrell D, (2014) Efavirenz Promotes b-Secretase Expression and Increased Ab1-40,42 via Oxidative Stress and Reduced Microglial Phagocytosis: Implications for HIV Associated Neurocognitive Disorders (HAND). PLoS ONE; 9: e95500. doi: 10.1371/journal.pone.0095500 24759994 PMC3997351 · DOI
  5. Bu XL, Xiang Y, Jin WS, (2017) Blood-derived amyloid-β protein induces Alzheimer’s disease pathologies. Mol.Psychiatry 00: 1– 9 29086767
  6. Chen M, Inestrosa NC, Ross GS, (1995) Platelets are the primary source of amyloidβ-peptide in human blood. Biochem Bioph Res Com. 213: 96– 103 7639768
  7. Citron M, Vigo-Pelfrey C, Teplow DB, (1994) Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci USA 91: 11993– 11997. 7991571 PMC45362
  8. Daily A, Nath A, Hersh LB (2006) Tat peptides inhibit neprilysin. J NeuroVirology 12: 153– 160. 16877296
  9. Deane R, Zlokovic BV (2007) Role of the blood-brain barrier in the pathogenesis of Alzheimer’s disease. Curr Alzheimer Res. 4: 191– 197. 17430246
  10. Deane R, Bell RD, Sagare A, Zlokovic BV (2009) Clearance of amyloid-β peptide across the blood-brain barrier: Implication for therapies in Alzheimer’s disease. CNS Neurol Disord Drug Targets 8: 16– 30. 19275634 PMC2872930
  11. de Almeida SM, Ribeiro CE, de Pereira AP, (2013) Neurocognitive impairment in HIV-1 clade C- versus B-infected individuals in Southern Brazil. J Neurovirol 19: 550– 556. 24277437 PMC3923762
  12. de Almeida SM, Tang B, Ribeiro CE, (2018A) Neprilysin in the Cerebrospinal Fluid and Serum of Patients Infected with HIV1-Subtypes C and B. J Acquir Immune Defic Syndr. 78: 248– 256. 29481488 PMC5953803
  13. de Almeida SM, Ribeiro CE, Rotta I, (2018B) Biomarkers of neuronal injury and amyloid metabolism in the cerebrospinal fluid of patients infected with HIV-1 subtypes B and C. J Neurovirol. 24: 28– 40. 29063514 PMC5792298
  14. El Ali A, Rivest S. The role of ABCB1 and ABCA1 in beta-amyloid clearance at the neurovascular unit in Alzheimer’s disease (2013) Front Physiol. 4: 45 DOI: 10.3389/fphys.2013.00045 23494712 PMC3595512 · DOI
  15. Esiri MM, Biddolph SC, Morris CS (1998) Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry 65: 29– 33. 9667557 PMC2170157
  16. Evin G, Zhu A, Holsinger RM, (2003) Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets. J Neurosci Res. 74: 386– 392. 14598315
  17. Gisslén M, Krut J, Andreasson U, (2009) Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurology 9: 63 20028512 PMC2807422
  18. Giunta B, Zhou Y, Hou H, (2008) HIV-1 TAT Inhibits Microglial Phagocytosis of Abeta Peptide. Int J Clin Exp Pathol. 1: 260– 275. 18784813 PMC2480563
  19. Graff-Radford NR, Crook JE, Lucas J, (2007) Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 64: 354– 362. 17353377
  20. Gross AM, Jaeger PA, Kreisberg JF, (2016) Methylome-wide Analysis of Chronic HIV Infection Reveals Five-Year Increase in Biological Age and Epigenetic Targeting of HLA. Mol Cell 62: 157– 168. 27105112 PMC4995115
  21. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297: 353– 356. 12130773
  22. High KP, Brennan-Ing M, Clifford DB, (2012) HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr. 60: S1– 18. 22688010 PMC3413877
  23. Johnston JA, Liu WW, Coulson DT, (2008) Platelet beta-secretase activity is increased in Alzheimer's disease. Neurobiol Aging 29: 661– 668. 17174011
  24. Kim J, Yoon JH, Kim YS (2013) HIV-1 Tat interacts with and regulates the localization and processing of amyloid precursor protein. PLoS One. 29; 8: e77972. PMC3843664 24312169
  25. Knight R, Khondoker M, Magill N, Stewart R, Landau S (2018) A Systematic Review and Meta-Analysis of the Effectiveness of Acetylcholinesterase Inhibitors and Memantine in Treating the Cognitive Symptoms of Dementia. Dement Geriatr Cogn Disord 45: 131– 151. 29734182
  26. Krut JJ, Zetterberg H, Blennow K, (2013) Cerebrospinal fluid Alzheimer’s biomarker profiles in CNS infections. J Neurol. 260: 620– 26. 23052602
  27. Kuo YM, Kokjohn TA, Watson MD, (2000) Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism. Am J Pathol. 156: 797– 805. 10702395 PMC1876838
  28. Lan X, Xu J, Kiyota T (2011) HIV-1 reduces Abeta-degrading enzymatic activities in primary human mononuclear phagocytes. J Immunol. 186: 6925– 32. 21551363 PMC3110566
  29. Lan X, Kiyota T, Hanamsagar R, (2012) The Effect of HIV Protease Inhibitors on Amyloid-β Peptide Degradation and Synthesis in Human Cells and Alzheimer’s Disease Animal Model. J Neuroim Pharmacol. 7: 412– 423. PMC3223330 21826404
  30. Letendre S, Ellis R, Deutsch R, (2010) Correlates of time-to-loss-of-viral response in CSF and plasma in the CHARTER cohort. Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA 16-19 February (poster 430).
  31. Lewczuk P, Matzenc A, Blennowd K, (2017) Cerebrospinal fluid AB42/40 Corresponds better than AB42 to amyloid PET in Alzheimer’s Disease. Journal of Alzheimer’s Disease 55: 813– 822 PMC5147502 27792012
  32. Liu WW, Todd S, Craig D, (2007) Elevated platelet beta-secretase activity in mild cognitive impairment. Dement Geriatr Cogn Disord. 24: 464– 468. 17986817
  33. Lopez OL, Kuller LH, Mehta PD, (2008) Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 70: 1664– 1671. 18401021 PMC2670993
  34. Mankowski JL, Queen SE, Tarwater PM, (2002) Accumulation of b-amyloid precursor protein in axons correlates with CNS expression of SIV gp41. J Neuropathol Exp Neurol. 61: 85– 90 11829347
  35. Marks KM, Clarke RM, Bussel JB, (2009) Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy. J Acquir Immune Defic Syndr. 52: 595– 599. 19734800 PMC2787779
  36. McKhann GM, Knopman DS, Chertkow H, (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7: 263– 9. 21514250 PMC3312024
  37. Mehta PD, Pirttila T, Mehta SP, (2000) Plasma and Cerebrospinal fluid levels of amyloid BProteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 57: 100– 105. 10634455
  38. Molinuevo JL, Gispert JD, Dubois B, (2013) The AD-CSF-Index discriminates Alzheimer’s disease patients from healthy controls: a validation study. J Alzheimers Dis. 36: 67– 77. 23524657
  39. Mooney S, Tracy R, Osler T, (2015) Elevated biomarkers of inflammation and coagulation in patients with HIV are associated with higher Framingham and VACS risk index scores. PLoS One 10: e0144312. 26641655 PMC4671539
  40. Nath A, Hersh LB (2005) Tat and amyloid: multiple interactions. AIDS 19: 203– 4. 15668546
  41. Noel N, Boufassa F, Lecuroux C, (2014) Elevated IP10 levels are associated with immune activation and low CD4(+) T-cellcounts in HIV controller patients. AIDS 28: 467– 476. 24378753
  42. Peterson J, Gisslen M, Zetterberg H, (2014) Cerebrospinal Fluid (CSF) Neuronal Biomarkers across the Spectrum of HIV Infection: Hierarchy of Injury and Detection. PLoS ONE 9: e116081. doi: 10.1371/journal.pone.0116081 25541953 PMC4277428 · DOI
  43. Pulliam L (2009) HIV regulation of amyloid beta production. J Neuroim Pharmacol. 4: 213– 217. 19288202
  44. Raboni SM, Ribeiro CE, Almeida SM, (2017) Impact of public health strategies on reducing AIDS mortality in southern Brazil. Int J STD AIDS 28: 54– 62. 26729764
  45. Rempel HC, Pulliam L (2005) HIV-1Tat inhibits neprilysin and elevates amyloid beta. AIDS 19: 127– 35. 15668537
  46. Toledo JB, Shaw LM, Trojanowski JQ (2013) Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker. Alzheimers Res Ther. 5: 8. doi: 10.1186/alzrt162. PubMed: 23470128. 23470128 PMC3706955 · DOI
  47. Tran H, Robinson S, Mikhailenko I, (2003) Modulation of the LDL receptor and LRP levels by HIV protease inhibitors. J Lipid Res. 44: 1859– 1869. 12837856
  48. van der Kant R, Goldstein LSB (2015) Cellular Functions of the Amyloid Precursor Protein from Development to Dementia. Dev. Cell 32: 23. 25710536
  49. Van Nostrand WE, Melchor JP (2001) Disruption of pathologic amyloid beta-protein fibril assembly on the surface of cultured human cerebrovascular smooth muscle cells. Amyloid 8: 20– 27. 11676286
  50. van Oijen M, Hofman A, Soares HD, (2006) Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 5: 655– 660. 16857570
  51. Wang MJ, Yi SH, Han J, (2017) Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease. Alzheimer's Res Ther. 9: 98 29246249 PMC5732503
  52. White JA, Manelli AM, Holmberg KH, (2005) Differential effects of oligomeric and fibrillar amyloid-beta 1–42 on astrocyte-mediated inflammation. Neurobiol Dis. 18: 459– 65. 15755672
  53. Wood SN (2006) Generalized Additive Models: An Introduction with R. Boca Raton, FL: CRC Press, LLC.
  54. Xu J, Ikezu T (2009) The comorbidity of HIV-associated neurocognitive disorders and Alzheimer’s disease: a foreseeable medical challenge in post-HAART era. J Neuroim Pharmacol. 4: 200– 212. PMC2682636 19016329
  55. Zhang J, Liu J, Katafiasz B, (2011) HIV-1 gp120- induced axonal injury detected by accumulation of beta-amyloid precursor protein in adult rat corpus callosum. J Neuroim Pharmacol. 6: 650– 7. PMC3165079 21286834

Cited by

Sorted by citations

Authors
The HIV Neurobehavioral Research Center (HNRC) Group, de Almeida, S. M., Ribeiro, C. E., Rotta, I., Letendre, S., Potter, M., Tang, B., Batistela, M., Vaida, F., & Ellis, R. J.
Affiliations
  • Hospital de Clínicas Universidade Federal do Paraná (BR)
  • University of California San Diego (US)
ORCID
Venue
Journal of NeuroVirology
Publisher
Springer Science and Business Media LLC
Published
2019-07-07
Volume
26
Issue
1
Pages
3-13
ISSN
  • 1355-0284 (ISSN-L)
  • 1538-2443
DOI
10.1007/s13365-019-00783-6
PMC
PMC6944779
OpenAlex
W2954330237
Cited by
14
References
1
Citations by year
2026: 1 · 2025: 2 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 1
FWCI
1.37
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of NeuroVirology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institute of Mental Health (R21 MH076651-01)
  • Center for AIDS Research, University of California, San Diego (International Pilot Grant P30 AI036214)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Health Sciences › Medicine › Emergency Medicine › HIV-related health complications and treatments
Keywords
HIV-1, HIV subtype B, HIV subtype C, amyloid-beta isoforms, Aβ42/Aβ40 ratio, Alzheimer's disease, cerebrospinal fluid biomarkers, CD4 recovery, HIV-associated neurocognitive disorders, amyloid processing
MeSH terms
Adult, Aged, Alzheimer Disease, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, HIV-1, HIV Infections, Amyloid beta-Peptides, CD4 Lymphocyte Count, Viral Load, Protein Isoforms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review